Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLXBiotechnology
+$0.14 today
- Market cap
- $3.42B
- Beta
- -0.16
- P/E (TTM)
- -11.3
- EPS (TTM)
- -$1.36
Volume 1.51M
Average 1.21M
AMLX Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX
Revenue · Q3 FY2026 · quarter ended Sep 2026
Revenue remains negative
Q3 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $0.
Context
- Revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Revenue history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 87.37M | -77.1% |
| FY2023 | 2023-12-31 | 380.79M | +1612.9% |
| FY2022 | 2022-12-31 | 22.23M | — |
| FY2021 | 2021-12-31 | 0 | — |
Revenue vs competitors
How AMLX compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +100.0% is the highest of 6, against a peer median of -61.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $959.76M USD | -0.7% | +17.1% | |
| LTM Mar 2026 | $57.94M USD | -58.0% | -43.6% | |
| LTM Mar 2026 | CHF 3.7M CHF | -86.9% | -3.2% | |
| LTM Jun 2026 | $3.6M USD | — | — | |
| LTM Mar 2026 | $134K USD | -61.7% | -24.9% | |
| LTM Sep 2026 | $0 USD | +100.0% | — | |
| LTM Sep 2026 | $0 USD | -100.0% | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Dec 2025 | $0 USD | — | — | |
| LTM Jun 2026 | $0 USD | — | — | |
| Peer median (excluding AMLX) | — | -61.7% | -14.1% | |
Competitors are the stored peer set for AMLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 22.23M | 380.79M | 87.37M | 0 |
| Cost of Revenue | 0 | 2.99M | 25.44M | 42.16M | 525K |
| Gross Profit | 0 | 19.24M | 355.35M | 45.22M | (525K) |
| Gross Margin | — | 86.5% | 93.3% | 51.8% | — |
| Research & Development | 44.04M | 93.45M | 128.19M | 104.08M | 90.4M |
| Selling, General & Admin | 38.93M | 127.13M | 188.36M | 114.33M | 62.89M |
| Operating Expenses | 82.69M | 220.58M | 316.54M | 359.95M | 152.77M |
| Depreciation & Amortization | 52K | 487K | 1.09M | 904K | 525K |
| EBITDA | (87.88M) | (197.11M) | 55.39M | (290.98M) | (144.16M) |
| EBITDA Margin | — | -886.7% | 14.5% | -333.0% | — |
| Operating Income | (82.69M) | (201.34M) | 38.8M | (314.73M) | (153.29M) |
| Operating Margin | — | -905.7% | 10.2% | -360.2% | — |
| Interest Income | 36K | 4.29M | 16.16M | 13.81M | 9.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (5.24M) | 3.74M | 15.5M | 12.6M | 8.6M |
| Income Before Tax | (87.93M) | (197.6M) | 54.3M | (302.14M) | (144.69M) |
| Pre-Tax Margin | — | -888.9% | 14.3% | -345.8% | — |
| Income Tax Expense | 0 | 774K | 5.03M | (393K) | 46K |
| Net Income | (87.93M) | (198.38M) | 49.27M | (301.74M) | (144.74M) |
| Net Margin | — | -892.4% | 12.9% | -345.4% | — |
| EPS (Basic) | (1.52) | (2.98) | 0.73 | (4.43) | (1.53) |
| EPS (Diluted) | (1.52) | (2.98) | 0.70 | (4.43) | (1.53) |
| Weighted Avg Shares | 57.86M | 66.51M | 67.23M | 68.14M | 94.57M |
| Weighted Avg Shares (Diluted) | 57.86M | 66.51M | 69.99M | 68.14M | 94.57M |
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
Intrinsic Alpha fair value
Locked
Current Price
$26.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.